WXIBF

$5.16

$

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.

Next Earnings

2026-02-25

Beta

0.474

Average Volume

Market Cap

Last Dividend

CIK

ISIN

KYG970081173

CUSIP

CEO

Zhisheng Chen

Sector

Healthcare

Industry

Biotechnology

Full Time Employees

12575

IPO Date

2018-01-30

Status

Active

Algorithm Performance

Upgrade To Premium for Full Access
Algorithm Profit/Loss Profit Factor # Trades Sharpe Sortino Efficiency